GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis,” published in the February 2025 issue of American College of Rheumatology by Wechsler et al. Eosinophilic ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used benralizumab, according to a poster presented here. Lower blood eosinophil counts ...

The prescribed dosage for Nucala (mepolizumab) may vary depending on a person’s individual treatment plan, specific diagnosis, and age. Typically, Nucala is given once every 4 weeks as a ...

Nucala (mepolizumab) is a prescription drug used to treat a certain kind of asthma and some other immune-related conditions. The drug is typically given once every 4 weeks as an injection under ...